| News
University Hospital Basel treats coronavirus patients with plasma
02.04.2020
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.

Blood cells (img: geralt/Pixabay)
According to a press release from the University Hospital Basel, the plasma that was administered to two Covid-19 patients contains “above all proteins such as coagulation factors and immunoglobulins (antibodies against pathogens).” Since this was the plasma from a patient who had recovered from Covid-19, the plasma also contains proteins that protect against this specific virus. This method has already proven successful against Ebola and swine flu. However, it remains to be seen whether this will be the case with coronavirus as well.
Andreas Buser, Head of the Basel Blood Donation Center, is quoted in an article by SRF, saying: “We have just treated a handful of patients in this way. Only a study will be able to demonstrate whether this treatment actually works.” Together with Manuel Battegay, Chief Physician of Infectiology at the University Hospital Basel, Buser heads up a research group conducting the potential treatment. This group will now follow developments. The hope is that this will be able to decrease the severity and duration of the illness. Battegay tells SRF: “We are currently collecting the initial experience.”
Giving blood is voluntary for patients who have been proven to have recovered from the virus. The University Hospital Basel states that donors are tested for diseases that can be transmitted by blood, and after donating “a range of viruses, bacteria and parasites as well as potentially harmful white blood cells” are neutralized. The recipient is then given the plasma by transfusion via the veins.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read MoreBasel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....
Read MoreRoche and Novartis among global leaders for research spending
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...
Read MoreRoche to found Institute for Human Biology
Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...
Read MoreProvectis establishes presence in Basel
Provectis Healthcare has chosen Basel as the location for its headquarters. The company is striving to become the partner of...
Read MoreAlentis raises 105 million US dollars
Alentis Therapeutics has received 105 million US dollars in a series C funding round. It will invest the funds in...
Read MoreSpirecut establishes presence in the Basel Area
Spirecut has opted to establish its new headquarters in the canton of Basel-Landschaft. The company is now operating out of...
Read MoreEvolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read More